PH12018501133A1 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer

Info

Publication number
PH12018501133A1
PH12018501133A1 PH12018501133A PH12018501133A PH12018501133A1 PH 12018501133 A1 PH12018501133 A1 PH 12018501133A1 PH 12018501133 A PH12018501133 A PH 12018501133A PH 12018501133 A PH12018501133 A PH 12018501133A PH 12018501133 A1 PH12018501133 A1 PH 12018501133A1
Authority
PH
Philippines
Prior art keywords
treating cancer
thiadiazole compounds
compound
formula
taken together
Prior art date
Application number
PH12018501133A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
David Robert Perkins
Johannes Wilhelmus Maria Nissink
Piotr Antoni Raubo
Peter Duncan Smith
Andrew Bailey
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of PH12018501133A1 publication Critical patent/PH12018501133A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12018501133A 2015-11-30 2018-05-29 1,3,4-thiadiazole compounds and their use in treating cancer PH12018501133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
PH12018501133A1 true PH12018501133A1 (en) 2019-01-21

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018501133A PH12018501133A1 (en) 2015-11-30 2018-05-29 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (28)

Country Link
US (1) US10040789B2 (enExample)
EP (1) EP3383872B1 (enExample)
JP (1) JP6821680B2 (enExample)
KR (1) KR20180083411A (enExample)
CN (1) CN108349965B (enExample)
AR (1) AR106875A1 (enExample)
AU (1) AU2016361834B2 (enExample)
BR (1) BR112018008330B1 (enExample)
CA (1) CA3005517C (enExample)
CL (1) CL2018001409A1 (enExample)
CO (1) CO2018006930A2 (enExample)
DK (1) DK3383872T3 (enExample)
DO (1) DOP2018000135A (enExample)
EA (1) EA035519B9 (enExample)
ES (1) ES2796562T3 (enExample)
IL (1) IL259508A (enExample)
MX (1) MX2018006483A (enExample)
MY (1) MY195680A (enExample)
NI (1) NI201800063A (enExample)
NZ (1) NZ743699A (enExample)
PE (1) PE20181522A1 (enExample)
PH (1) PH12018501133A1 (enExample)
SG (1) SG11201803808VA (enExample)
SV (1) SV2018005700A (enExample)
TN (1) TN2018000118A1 (enExample)
TW (1) TW201731511A (enExample)
WO (1) WO2017093301A1 (enExample)
ZA (1) ZA201804361B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
WO2020078350A1 (zh) * 2018-10-16 2020-04-23 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途
WO2025196447A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors
WO2025196446A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN111892589A (zh) 2014-01-06 2020-11-06 理森制药股份公司 谷氨酰胺酶抑制剂
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
SG11201803808VA (en) 2018-06-28
EA035519B9 (ru) 2020-08-10
BR112018008330B1 (pt) 2023-03-07
MX2018006483A (es) 2019-08-12
AU2016361834B2 (en) 2019-11-14
SV2018005700A (es) 2019-03-07
JP6821680B2 (ja) 2021-01-27
US10040789B2 (en) 2018-08-07
US20170333429A1 (en) 2017-11-23
EA201891239A1 (ru) 2018-11-30
KR20180083411A (ko) 2018-07-20
EP3383872A1 (en) 2018-10-10
CL2018001409A1 (es) 2018-12-07
AR106875A1 (es) 2018-02-28
EP3383872B1 (en) 2020-05-20
AU2016361834A1 (en) 2018-07-12
CO2018006930A2 (es) 2018-10-10
ES2796562T3 (es) 2020-11-27
DK3383872T3 (da) 2020-06-08
MY195680A (en) 2023-02-03
CA3005517C (en) 2023-12-12
WO2017093301A1 (en) 2017-06-08
CA3005517A1 (en) 2017-06-08
TN2018000118A1 (en) 2019-10-04
PE20181522A1 (es) 2018-09-24
ZA201804361B (en) 2019-07-31
DOP2018000135A (es) 2018-06-30
NZ743699A (en) 2023-02-24
EA035519B1 (ru) 2020-06-29
JP2018535235A (ja) 2018-11-29
BR112018008330A2 (pt) 2018-10-30
CN108349965A (zh) 2018-07-31
NI201800063A (es) 2018-10-18
IL259508A (en) 2018-07-31
CN108349965B (zh) 2021-10-26
TW201731511A (zh) 2017-09-16

Similar Documents

Publication Publication Date Title
PH12018501133A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
GEP20227428B (en) Heterocyclic compounds as immunomodulators
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12016502081B1 (en) Compounds for treating spinal muscular atrophy
MX2016011897A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
PH12018501131A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12020552261A1 (en) Proteasome activity enhancing compounds
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
MX2021015514A (es) Compuesto heterociclico.
GEP20186893B (en) Pyrazines modulators of gpr6
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
MX2018006528A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer.
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2021003481A (es) Compuesto heterociclico.
MX2018006374A (es) Compuestos de bis-piridazina y su uso en el tratamiento del cancer.
MX2019015747A (es) Compuesto heterociclico.